Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
2011· article· en· New England Journal of Medicine· Biochemistry, Genetics and Molecular Biology
aff
7 688
citations
Travaux
Tous les travaux de la base. Chaque rangée indique les voies par lesquelles le travail a été admis, car une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée.
Voie
Domaine
Type
Langue
Période
à
Consensus du tri
Ordre
Indicateurs
Données de dépistage
Les étiquettes directes sont rares et non validées. Une absence reste inconnue.
1 filtre actif
10 000+ travauxpage 1
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
2001· article· en· New England Journal of Medicine· Medicine
aff
6 149
citations
Abiraterone and Increased Survival in Metastatic Prostate Cancer
2011· article· en· New England Journal of Medicine· Medicine
aff
4 394
citations
The enduring effects of abuse and related adverse experiences in childhood
2005· article· en· European Archives of Psychiatry and Clinical Neuroscience· Psychology
affsans résumé
4 237
citations
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
2007· article· en· Journal of Clinical Oncology· Medicine
affabout
3 859
citations
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007· article· en· New England Journal of Medicine· Medicine
aff
3 647
citations
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
2006· article· en· New England Journal of Medicine· Medicine
aff
3 481
citations
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
2013· article· en· New England Journal of Medicine· Medicine
aff
3 395
citations
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis
2000· article· en· JAMA· Medicine
aboutno aff
3 166
citations
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
2019· article· en· The Lancet· Medicine
affsans résumé
3 040
citations
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
2012· article· en· The Lancet· Biochemistry, Genetics and Molecular Biology
affsans résumé
2 960
citations
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
2018· review· en· The Lancet· Medicine
affsans résumé
2 818
citations
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013· review· en· Advanced Drug Delivery Reviews· Materials Science
fundno affsans résumé
2 762
citations
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006· article· en· The Lancet· Medicine
affsans résumé
2 595
citations
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009· article· en· New England Journal of Medicine· Medicine
aff
2 571
citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
2018· article· en· The Lancet Oncology· Medicine
affsans résumé
2 536
citations
B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis
2008· article· en· New England Journal of Medicine· Medicine
aff
2 399
citations
The Canadian Adverse Events Study: the incidence of adverse events among hospital patients in Canada
2004· article· en· Canadian Medical Association Journal· Health Professions
afffundvenueabout
2 350
citations
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial
2006· article· en· Gastroenterology· Biochemistry, Genetics and Molecular Biology
affsans résumé
2 250
citations
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
2009· article· en· Journal of Clinical Oncology· Medicine
fundno aff
2 189
citations
Treatment of HCV Infection by Targeting MicroRNA
2013· article· en· New England Journal of Medicine· Medicine
aff
2 186
citations
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
2009· article· en· Journal of Clinical Oncology· Medicine
aboutno aff
2 130
citations
Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture
2007· article· en· New England Journal of Medicine· Medicine
aff
1 995
citations
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
2019· article· en· Journal of Clinical Oncology· Medicine
aff
1 819
citations
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
2007· article· en· New England Journal of Medicine· Medicine
aff
1 793
citations